Literature DB >> 8725715

The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.

S Kitchen1, F E Preston.   

Abstract

The activated partial thromboplastin time (APTT) is the most commonly used test for laboratory monitoring of unfractionated heparin therapy. Since there are differences between APTT reagents in respect of responsiveness to heparin the widely used therapeutic range of 1.5-2.5 (APTT ratios) may not be appropriate for all reagents. The aim of this study was to assess the relationship between 6 different APTT reagents using a manual technique, 2 of these reagents used in combination with a coagulometer, a heparin assay by protamine titration and a chromogenic anti-Xa assay. Samples from 42 patients treated with unfractionated heparin for thromboembolic disease were studied, 12 of whom were receiving warfarin therapy with International Normalised Ratios (INR) of > 1.3. For normal subjects, APTT results were highly dependent on the method used and statistically significant differences were noted. The ratio of patient to mean normal APTT was calculated for each APTT method. When 30 samples from heparinised patients (with INRs of < 1.3) were analysed manually, the APTT ranges equivalent to 0.2-0.4 u/ml heparin by protamine titration (by regression analysis) were 1.6-1.9 for Boehringer reagent (the least responsive) up to 2.2-2.9 for Instrumentation Laboratory reagent (the most responsive). The concentration of heparin associated on average with APTT ratios of 1.5-2.5 varied approximately twofold to threefold between reagents.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725715

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Comparison of two different ecarin clotting time methods.

Authors:  Tivadar Fenyvesi; Job Harenberg; Christel Weiss; Ingrid Jörg
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

2.  Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects.

Authors:  Pascale Gaussem; M Dubar; B le Bonniec; I Richard-Lordereau; R Jochemsen; M Aiach
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

Review 3.  Current therapeutic approaches in the management of hemophilia-a consensus view by the Romanian Society of Hematology.

Authors:  Ionut Hotea; Melen Brinza; Cristina Blag; Alina-Andreea Zimta; Noemi Dirzu; Corina Burzo; Ioana Rus; Dragos Apostu; Horea Benea; Mirela Marian; Alexandru Mester; Sergiu Pasca; Sabina Iluta; Patric Teodorescu; Ciprian Jitaru; Mihnea Zdrenghea; Anca Bojan; Tunde Torok-Vistai; Radu Niculescu; Cristina Tarniceriu; Delia Dima; Cristina Truica; Margit Serban; Ciprian Tomuleasa; Daniel Coriu
Journal:  Ann Transl Med       Date:  2021-07

4.  Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy.

Authors:  Kevin McLaughlin; Jessica Rimsans; Katelyn W Sylvester; John Fanikos; David M Dorfman; Patricia Senna; Jean M Connors; Samuel Z Goldhaber
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

5.  Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement.

Authors:  Benjamin Lardinois; Michaël Hardy; Isabelle Michaux; Geoffrey Horlait; Thomas Rotens; Hugues Jacqmin; Sarah Lessire; Pierre Bulpa; Alain Dive; François Mullier
Journal:  J Clin Med       Date:  2022-02-28       Impact factor: 4.241

6.  Monitoring of anticoagulant therapy in heart disease: considerations for the current assays.

Authors:  Mohammadali Boroumand; Hamidreza Goodarzynejad
Journal:  J Tehran Heart Cent       Date:  2010-05-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.